Evidence map›Paper›PMID 30343356›Full record

ReviewJournal of endocrinological investigation2018

Testosterone deficiency in non-cancer opioid-treated patients.

F Coluzzi, D Billeci, M Maggi, G Corona

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of endocrinological investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 7 pooled it
6.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 7 syntheses or guidelines pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Opioids and Their Endocrine Effects: A Systematic Review and Meta-analysis.The Journal of clinical endocrinology and metabolism · 2020
    Pooled it
  7. Guideline
  8. Article
  9. Article
  10. Review
  11. Review
  12. Role of TRP Channels in Cancer-Induced Bone Pain.International journal of molecular sciences · 2025
    Review
  13. Article
  14. Article
  15. A Closer Look at Opioid-Induced Adrenal Insufficiency: A Narrative Review.International journal of molecular sciences · 2023
    Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

F ColuzziDepartment of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.ORCID http://orcid.org/0000-0001-7184-5519
D BilleciNeurosurgical Department, ULSS2 Treviso Hospital, University of Padua, Treviso, Italy.
M MaggiDepartment of Experimental and Clinical Biomedical Sciences, Sexual Medicine and Andrology Unit, University of Florence, Florence, Italy.
G CoronaEndocrinology Unit, Medical Department, Azienda Usl di Bologna, Maggiore-Bellaria Hospital, Largo Nigrisoli 2, 40133, Bologna, Italy. jocorona@libero.it.
Azienda USL di Bologna · ITSapienza University of Rome · ITUniversity of Florence · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe use of opioids in patients with chronic non-cancer pain is common and can be associated with opioid-induced androgen deficiency (OPIAD) in men. This review aims to evaluate the current literature regarding the prevalence, clinical consequence and management of OPIAD.

methodsA database search was performed in Medline, Embase and Cochrane using terms such as "analgesics", "opioids" and "testosterone". Relevant literature from January 1969 to March 2018 was evaluated.

resultsThe prevalence of patients with OPIAD ranges from 19 to 86%, depending on the criteria for diagnosis of hypogonadism. The opioid-induced suppression of gonadotropin-releasing and luteinizing hormones represents the main important pathogenetic mechanisms. OPIAD has significant negative clinical consequences on sexual function, mood, bone density and body composition. In addition, OPIAD can also impair pain control leading to hyperalgesia, which can contribute to sexual dysfunction and mood impairment.

conclusionsOPIAD is a common adverse effect of opioid treatment and contributes to sexual dysfunction, impairs pain relief and reduces overall quality of life. The evaluation of serum testosterone levels should be considered in male chronic opioid users and the decision to initiate testosterone treatment should be based on the clinical profile of individuals, in consultation with the patient.

Indexed as

Analgesics, OpioidHumansHypogonadismTestosteroneAnalgesics, OpioidTestosteroneChronic non-cancer painOpioid-induced androgen deficiencyOpioidsTestosterone

Identifiers

PMID30343356
PMCPMC6244554
OpenAlexW2897436693

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.